Art. -Nr.: HY-N0095

(S)-10-Hydroxycamptothecin

(Synonyms: 10-HCPT; 10-Hydroxycamptothecin)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

(S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is a DNA topoisomerase I inhibitor of isolated from the Chinese plant Camptotheca accuminata. (S)-10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia treatment.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.74%
CAS. Nr.: 19685-09-7
Formel: C₂₀H₁₆N₂O₅
Molecular Weight:364.35

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

(S)-10-Hydroxycamptothecin Chemical Structure

CAS. Nr.: 19685-09-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[3]

Topoisomerase I

Alle Topoisomerase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.004 μM Compound: 2	Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human A2780 cells overexpressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
A2780	IC₅₀	0.7 μM Compound: 2, HCPT	Cytotoxicity against human A2780 cells after 48 hrs by MTT assay Cytotoxicity against human A2780 cells after 48 hrs by MTT assay	[PMID: 19715319]
A-375	IC₅₀	0.15 μM Compound: HCPT	Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A375 cells after 72 hrs by sulforhodamine B assay	[PMID: 23639650]
A-375	IC₅₀	27.8 μM Compound: HCPT	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 25874331]
A-375	IC₅₀	27.8 μM Compound: HCPT	Cytotoxicity against human A375 cells after 72 hrs by MTT assay Cytotoxicity against human A375 cells after 72 hrs by MTT assay	[PMID: 26280921]
A549	IC₅₀	0.07 μM Compound: 10-OH CPT	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 23566520]
A549	IC₅₀	0.08 μM Compound: 10-HCPT	Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human A549 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
A549	IC₅₀	0.082 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 26725027]
A549	IC₅₀	0.11 μM Compound: 6, CPT-OH	Antitumor activity against human A549/ATCC cells by SRB method Antitumor activity against human A549/ATCC cells by SRB method	[PMID: 19541483]
A549	IC₅₀	0.12 μM Compound: HCPT	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth inhibition incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth inhibition incubated for 48 hrs by CCK-8 assay	[PMID: 38350361]
A549	IC₅₀	0.3 μM Compound: HCPT	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	[PMID: 23639650]
A549	IC₅₀	0.8 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27836197]
A549	IC₅₀	0.8 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28441581]
A549	IC₅₀	1.75 μM Compound: HCPT	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
A549	IC₅₀	2.75 μM Compound: HCPT	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 30108853]
A549	IC₅₀	33.6 nM Compound: 10-HCPT	Cytotoxicity against human A549 after 72 hrs by SRB assay Cytotoxicity against human A549 after 72 hrs by SRB assay	[PMID: 22647222]
A549	IC₅₀	9.13 μM Compound: HCPT	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30528976]
Bcap37	IC₅₀	>20 μM Compound: HCPT	Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 23124210]
Bcap37	IC₅₀	28.1 μM Compound: HCPT	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 25874331]
Bcap37	IC₅₀	28.1 μM Compound: HCPT	Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay Cytotoxicity against human Bcap37 cells after 72 hrs by MTT assay	[PMID: 26280921]
Bel-7402	IC₅₀	0.2 μM Compound: 10-OH CPT	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 23566520]
Bel-7402	IC₅₀	0.2 μM Compound: 2, HCPT	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay	[PMID: 19715319]
Bel-7402	IC₅₀	0.28 μM Compound: HCP	Cytotoxicity against human Bel-7402 cells after 72 hrs by sulforhodamine B assay Cytotoxicity against human Bel-7402 cells after 72 hrs by sulforhodamine B assay	[PMID: 17067169]
Bel-7402	IC₅₀	0.36 μM Compound: HCP	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 20184290]
Bel-7402	IC₅₀	0.4 μM Compound: HCP	Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay Cytotoxicity against human Bel7402 cells after 72 hrs by SRB assay	[PMID: 19133759]
Bel-7402	IC₅₀	0.62 μg/mL Compound: hydroxycamptothecin	Cytotoxicity against human Bel7402 cells Cytotoxicity against human Bel7402 cells	[PMID: 15104494]
Bel-7402	IC₅₀	2.47 μM Compound: 10-hydroxycamptothecin (HCPT)	Inhibitory concentration against human Bel-7402 liver cancer cell line Inhibitory concentration against human Bel-7402 liver cancer cell line	[PMID: 15808456]
CNE-2	IC₅₀	0.37 μM Compound: HCPT	Cytotoxicity against human CNE2 cells after 48 hrs by MTT assay Cytotoxicity against human CNE2 cells after 48 hrs by MTT assay	[PMID: 19423199]
CNE-2	IC₅₀	1.04 μM Compound: 10-HCT	Antitumor against human CNE2 cells assessed as cell survival after 48 hrs by MTT assay Antitumor against human CNE2 cells assessed as cell survival after 48 hrs by MTT assay	[PMID: 21600681]
COLO 205	IC₅₀	9.1 nM Compound: 2	Cytotoxicity against human Colo 205 cells assessed as inhibition of [3H]thymidine after 48 hrs Cytotoxicity against human Colo 205 cells assessed as inhibition of [3H]thymidine after 48 hrs	[PMID: 18318465]
HCT-116	IC₅₀	0.021 μM Compound: 10-HCPT	Cytotoxicity against human HCT-116 assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human HCT-116 assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
HCT-116	IC₅₀	0.05 μM Compound: 10-HCPT	Antiproliferative activity against human HCT-116 cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells incubated for 24 hrs by CCK-8 assay	[PMID: 35561631]
HCT-116	IC₅₀	0.148 μM Compound: 10-hydroxycamptothecin (HCPT)	Inhibitory concentration against human HCT116 colon cancer cell line Inhibitory concentration against human HCT116 colon cancer cell line	[PMID: 15808456]
HCT-116	IC₅₀	0.3 μM Compound: 10-OH CPT	Cytotoxicity against human HCT116 cells by MTT assay Cytotoxicity against human HCT116 cells by MTT assay	[PMID: 23566520]
HCT-116	IC₅₀	3.2 μM Compound: HCPT	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28441581]
HCT-116	IC₅₀	3.5 μM Compound: HCPT	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 27836197]
HCT-116	IC₅₀	31.2 nM Compound: 10-HCPT	Cytotoxicity against human HCT116 after 72 hrs by SRB assay Cytotoxicity against human HCT116 after 72 hrs by SRB assay	[PMID: 22647222]
HCT-116	IC₅₀	58.62 μM Compound: HCPT	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 26725027]
HCT-8	IC₅₀	0.181 μM Compound: 2	Antiproliferative activity against human HCT8 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HCT8 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
HeLa	IC₅₀	0.06 μM Compound: 10-HCPT	Antiproliferative activity against human HeLa cells incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells incubated for 24 hrs by CCK-8 assay	[PMID: 35561631]
HeLa	IC₅₀	10.04 μM Compound: HCPT	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28318943]
HeLa	IC₅₀	29.16 μM Compound: HCPT	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 28745887]
HeLa	IC₅₀	29.5 μM Compound: 10-hydroxy camptothecin	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 23092389]
HepG2	IC₅₀	0.499 μM Compound: 2	Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
HepG2	IC₅₀	0.981 μM Compound: 10-Hydroxy CPT	Antitumor activity against human HepG2 cells by WST-1 assay Antitumor activity against human HepG2 cells by WST-1 assay	[PMID: 21414778]
HepG2	IC₅₀	1.47 μM Compound: HCPT	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 30600208]
HepG2	IC₅₀	10.1 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 27836197]
HepG2	IC₅₀	10.21 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30528976]
HepG2	IC₅₀	10.3 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28441581]
HepG2	IC₅₀	2.27 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 26725027]
HepG2	IC₅₀	3.19 μM Compound: HCPT	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
HepG2	IC₅₀	3.7 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20402524]
HepG2	IC₅₀	5.4 nM Compound: 2	Cytotoxicity against human HepG2 cells assessed as inhibition of [3H]thymidine after 48 hrs Cytotoxicity against human HepG2 cells assessed as inhibition of [3H]thymidine after 48 hrs	[PMID: 18318465]
HepG2	IC₅₀	5.52 μM Compound: HCPT	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 28745887]
HepG2	IC₅₀	6.49 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human Hep G2 after 48 hrs by MTT assay Cytotoxicity against human Hep G2 after 48 hrs by MTT assay	[PMID: 16933867]
HL-60	IC₅₀	0.024 μg/mL Compound: hydroxycamptothecin	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 15104494]
HL-60	IC₅₀	0.04 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 20402524]
HL-60	IC₅₀	0.11 μM Compound: 5ak	Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells	[PMID: 8410981]
HL-60	IC₅₀	0.25 μM Compound: HCPT	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 23639650]
HL-60	IC₅₀	0.41 μM Compound: HCP	Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay Cytotoxicity against human HL-60 cells after 72 hrs by MTT assay	[PMID: 17067169]
HT-29	IC₅₀	0.21 μM Compound: 6, CPT-OH	Antitumor activity against human HT-29 cells by SRB method Antitumor activity against human HT-29 cells by SRB method	[PMID: 19541483]
HT-29	IC₅₀	8.8 nM Compound: 2	Cytotoxicity against human HT29 cells assessed as inhibition of [3H]thymidine after 48 hrs Cytotoxicity against human HT29 cells assessed as inhibition of [3H]thymidine after 48 hrs	[PMID: 18318465]
Huh-7	IC₅₀	1.35 μM Compound: HCPT	Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth inhibition incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth inhibition incubated for 48 hrs by CCK-8 assay	[PMID: 38350361]
HUVEC	IC₅₀	0.92 μM Compound: HCPT	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth inhibition incubated for 48 hrs by CCK-8 assay Cytotoxicity against HUVEC cells assessed as inhibition of cell growth inhibition incubated for 48 hrs by CCK-8 assay	[PMID: 38350361]
HUVEC	IC₅₀	18.2 μM Compound: HCPT	Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay Antiproliferative activity against human HUVEC cells after 48 hrs by MTT assay	[PMID: 28441581]
Jurkat	IC₅₀	0.03 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 20402524]
K562	IC₅₀	0.16 μM Compound: HCP	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 20184290]
K562	IC₅₀	4.1 μM Compound: HCP	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19133759]
KB	IC₅₀	0.128 μM Compound: 2	Antiproliferative activity against human KB cells after 48 hrs by CCK8 assay Antiproliferative activity against human KB cells after 48 hrs by CCK8 assay	[PMID: 25481395]
KB	IC₅₀	0.6 μM Compound: 10-OH CPT	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 23566520]
KB	IC₅₀	0.6 μM Compound: 2, HCPT	Cytotoxicity against human KB cells after 48 hrs by MTT assay Cytotoxicity against human KB cells after 48 hrs by MTT assay	[PMID: 19715319]
KB	IC₅₀	0.829 μM Compound: 10-Hydroxy CPT	Antitumor activity against human KB cells by WST-1 assay Antitumor activity against human KB cells by WST-1 assay	[PMID: 21414778]
L02	IC₅₀	10.23 μM Compound: HCPT	Antiproliferative activity against human HL-7702 cells after 48 hrs by MTT assay Antiproliferative activity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 30528976]
L02	IC₅₀	12.83 μM Compound: HCPT	Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay	[PMID: 30108853]
L02	IC₅₀	20.4 μM Compound: HCPT	Antiproliferative activity against human L02 cells after 48 hrs by MTT assay Antiproliferative activity against human L02 cells after 48 hrs by MTT assay	[PMID: 28441581]
L1210	IC₅₀	18 nM Compound: 2 (10-hydroxycamptothecin)	Inhibitory activity in mice bearing L1210 leukemia Inhibitory activity in mice bearing L1210 leukemia	[PMID: 1846923]
LoVo	IC₅₀	0.33 μM Compound: 10-HCPT	Cytotoxicity against human LoVo assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human LoVo assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32650182]
MCF7	IC₅₀	19.12 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human MCF7 after 48 hrs by MTT assay Cytotoxicity against human MCF7 after 48 hrs by MTT assay	[PMID: 16933867]
MCF7	IC₅₀	2.4 μM Compound: HCPT	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27836197]
MCF7	IC₅₀	2.8 μM Compound: HCPT	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28441581]
MCF7	IC₅₀	3.58 μM Compound: HCPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30600208]
MCF7	IC₅₀	48.2 μM Compound: HCPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25874331]
MCF7	IC₅₀	48.2 μM Compound: HCPT	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26280921]
MDA-MB-231	IC₅₀	0.06 μM Compound: 10-OH CPT	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 23566520]
MG-63	IC₅₀	10.69 μM Compound: HCPT	Antiproliferative activity against human MG63 cells after 48 hrs by MTT assay Antiproliferative activity against human MG63 cells after 48 hrs by MTT assay	[PMID: 30528976]
MGC-803	IC₅₀	>20 μM Compound: HCPT	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 23124210]
MGC-803	IC₅₀	15.19 μM Compound: HCPT	Antiproliferative activity against human MGC803 cells by MTT assay Antiproliferative activity against human MGC803 cells by MTT assay	[PMID: 28745887]
MGC-803	IC₅₀	29.1 μM Compound: HCPT	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 25874331]
MGC-803	IC₅₀	29.1 μM Compound: HCPT	Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay	[PMID: 26280921]
MGC-803	IC₅₀	6.55 μM Compound: HCPT	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
MGC-803	IC₅₀	6.55 μM Compound: HCPT	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 30108853]
MGC-803	IC₅₀	9.71 μM Compound: HCPT	Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 30528976]
NCI-H460	IC₅₀	10.08 μM Compound: HCPT	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 30528976]
NCI-H460	IC₅₀	16.59 μM Compound: HCPT	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 30108853]
NCI-H460	IC₅₀	38.55 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human NCI-H460 after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 after 48 hrs by MTT assay	[PMID: 16933867]
NCI-H460	IC₅₀	4.91 μM Compound: HCPT	Antiproliferative activity against human NCI-H460 cells by MTT assay Antiproliferative activity against human NCI-H460 cells by MTT assay	[PMID: 28745887]
P388	IC₅₀	12 nM Compound: 1	Inhibitory activity against P388 Leukemia cells Inhibitory activity against P388 Leukemia cells	[PMID: 12565975]
PC-3	IC₅₀	0.078 μM Compound: 2	Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay Cytotoxicity against human PC3 cells expressing alpha5beta3 integrin assessed as cell survival after 72 hrs by SRB assay	[PMID: 22959246]
PC-3	IC₅₀	34.5 μM Compound: HCPT	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 25874331]
PC-3	IC₅₀	34.5 μM Compound: HCPT	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 26280921]
SF-268	IC₅₀	29.88 μM Compound: 10-hydroxy-camptothecin	Cytotoxicity against human SF-268 after 48 hrs by MTT assay Cytotoxicity against human SF-268 after 48 hrs by MTT assay	[PMID: 16933867]
SGC-7901	IC₅₀	0.835 μM Compound: 2	Antiproliferative activity against human SGC7901 cells after 48 hrs by CCK8 assay Antiproliferative activity against human SGC7901 cells after 48 hrs by CCK8 assay	[PMID: 25481395]
SMMC-7721	IC₅₀	0.14 μM Compound: HCP	Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay Growth inhibition of human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 19842682]
T-24	IC₅₀	11.83 μM Compound: HCPT	Cytotoxicity against human T24 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human T24 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29921475]
T-24	IC₅₀	11.83 μM Compound: HCPT	Cytotoxicity against human T24 cells after 48 hrs by MTT assay Cytotoxicity against human T24 cells after 48 hrs by MTT assay	[PMID: 30108853]
T-24	IC₅₀	5.53 μM Compound: HCPT	Antiproliferative activity against human T24 cells by MTT assay Antiproliferative activity against human T24 cells by MTT assay	[PMID: 28745887]
Tumor Cell line	GI₅₀	36 nM Compound: 10-hydroxy-camptothecin	Mean GI50 against variety of human tumor cell lines Mean GI50 against variety of human tumor cell lines	[PMID: 11052802]
U-87MG ATCC	IC₅₀	2.92 μM Compound: HCPT	Antiproliferative activity against human U87 cells assessed as inhibition of cell growth inhibition incubated for 48 hrs by CCK-8 assay Antiproliferative activity against human U87 cells assessed as inhibition of cell growth inhibition incubated for 48 hrs by CCK-8 assay	[PMID: 38350361]
U-937	IC₅₀	0.11 μM Compound: 10-Hydroxycamptothecin	Cytotoxicity against human U937 cells after 48 hrs by MTT assay Cytotoxicity against human U937 cells after 48 hrs by MTT assay	[PMID: 20402524]

In Vitro

(S)-10-Hydroxycamptothecin (5-20 μg/L; 6 days; Hep G2 cells) treatment results in the cell cycle arrest at G2/M phase^[2].
(S)-10-Hydroxycamptothecin induces differentiation, down-regulates nuclear antigen (PCNA) and up-regulates wild-type protein p53 in Hep G2 cells^[2].
(S)-10-Hydroxycamptothecin inhibits L1210 leukemia cells with an IC₅₀ of 1.15 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[2]

Cell Line:

Hep G2 cells
Concentration:

5 µg/L, 10 µg/L, 20 µg/L
Incubation Time:

6 days
Result:

Hep G2 cells were mainly arrested at G2/M phase.

In Vivo

(S)-10-Hydroxycamptothecin (10-Hydroxycamptothecin) against L1210 leukemia in mice is tested. At the optimal dose (15 mg/kg), (S)-10-Hydroxycamptothecin has a 71% increase in life span (ILS)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 19685-09-7
Appearance Solid
Molecular Weight 364.35
Formel C₂₀H₁₆N₂O₅
Color Light yellow to yellow
SMILES

O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=CC(O)=CC=C5N=C4C3=C2)=O
Synonyms

10-HCPT; 10-Hydroxycamptothecin
Structure Classification
- Alkaloids
- Quinoline Alkaloids
- Alkaloids
- Pyrrole Alkaloids
- Phenols
- Monophenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

Commun Biol

A compatible gravity-driven organoid perfusion (GDOP) platform for drug screening with sensitivity and toxicity process evaluation. [Abstract]

2026 Apr 2;9(1):718. PMID: 41922471
J Cell Mol Med

Pharmacological Targeting of DHHC9-Mediated STRN4 Palmitoylation to Suppress YAP-Driven Cancer Metastasis. [Abstract]

2025 Sep;29(17):e70815. PMID: 40903842

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 10 mg/mL (27.45 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7446 mL

13.7231 mL

27.4461 mL

5 mM

0.5489 mL

2.7446 mL

5.4892 mL

10 mM

0.2745 mL

1.3723 mL

2.7446 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (6.86 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.86 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance . Journal of Drug Targeting.

[2]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8

[3]. Yu P, et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol Pharm Bull. 2012;35(8):1295-9. [Content Brief]

[4]. Zhang XW, et al. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin. 2000 Apr;21(4):364-8. [Content Brief]

[5]. Zhang XW, et al. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs. 2000 Oct;11(9):747-56. [Content Brief]

[6]. Liu M, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24(5):433-40. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7446 mL	13.7231 mL	27.4461 mL	68.6153 mL
	5 mM	0.5489 mL	2.7446 mL	5.4892 mL	13.7231 mL
	10 mM	0.2745 mL	1.3723 mL	2.7446 mL	6.8615 mL
	15 mM	0.1830 mL	0.9149 mL	1.8297 mL	4.5744 mL
	20 mM	0.1372 mL	0.6862 mL	1.3723 mL	3.4308 mL
	25 mM	0.1098 mL	0.5489 mL	1.0978 mL	2.7446 mL

Keywords

(S)-10-Hydroxycamptothecin

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

(S)-10-Hydroxycamptothecin

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Phenols Library

Traditional Chinese Medicine Active Compound Library

Alkaloids Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Chemotherapy Drug Library

Plant-Sourced Natural Product Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) (S)-10-Hydroxycamptothecin

Alle Topoisomerase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

(S)-10-Hydroxycamptothecin Related Classifications

HY-N0095 Related Classifications